subscribeSubscribe
Basilea returns cancer drug rights to Merck

Basilea returns cancer drug rights to Merck
Gabrielle Masson FIERCEBIOTECH
28 Jun 2022
Share Share
Basilea reports PC data on BAL0891, derazantinib and lisavanbulin at AACR

Basilea reports PC data on BAL0891, derazantinib and lisavanbulin at AACR
GLOBENEWSWIRE
13 Apr 2022
Share Share
Basilea reports updated interim results for iCCA patients with FGFR2 inhibitor

Basilea reports updated interim results for iCCA patients with FGFR2 inhibitor
GLOBENEWSWIRE
24 Jan 2022
Share Share
Basilea presents preclinical data on synergy between derazantinib and paclitaxel

Basilea presents preclinical data on synergy between derazantinib and paclitaxel
GLOBENEWSWIRE
11 Oct 2021
Share Share
Basilea presents full safety and efficacy data set on derazantinib in ESMO

Basilea presents full safety and efficacy data set on derazantinib in ESMO
GLOBENEWSWIRE
17 Sep 2021
Share Share
Basilea presents preclinical data on anti-angiogenic activity of derazantinib

Basilea presents preclinical data on anti-angiogenic activity of derazantinib
GLOBENEWSWIRE
26 Oct 2020
Share Share
Basilea reports interim results from ph1/2 study FIDES-02 exploring derazantinib

Basilea reports interim results from ph1/2 study FIDES-02 exploring derazantinib
GLOBENEWSWIRE
12 Oct 2020
Share Share
Basilea reports pooled efficacy data for derazantinib in iCCA patients FGFR2

Basilea reports pooled efficacy data for derazantinib in iCCA patients FGFR2
BASILEA
12 Oct 2020
Share Share
Basilea announces completion patient enrolment into first cohort of ph2 FIDES-01

Basilea announces completion patient enrolment into first cohort of ph2 FIDES-01
GLOBENEWSWIRE
20 Jul 2020
Share Share
Basilea initiates trial of derazantinib to treat urothelial cancer

Basilea initiates trial of derazantinib to treat urothelial cancer
CLINICALTRIAL SERANA
13 Aug 2019
Share Share